Cargando…
The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung di...
Autores principales: | Lanari, Marcello, Vandini, Silvia, Arcuri, Santo, Galletti, Silvia, Faldella, Giacomo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693113/ https://www.ncbi.nlm.nih.gov/pubmed/23840240 http://dx.doi.org/10.1155/2013/359683 |
Ejemplares similares
-
Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency
por: Lanari, Marcello, et al.
Publicado: (2014) -
Immunological, Viral, Environmental, and Individual Factors Modulating Lung Immune Response to Respiratory Syncytial Virus
por: Vandini, Silvia, et al.
Publicado: (2015) -
Respiratory syncytial virus infection in infants and correlation with meteorological factors and air pollutants
por: Vandini, Silvia, et al.
Publicado: (2013) -
Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection
por: Vandini, Silvia, et al.
Publicado: (2017) -
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
por: Biagi, Carlotta, et al.
Publicado: (2020)